Browne L Daniel 4
4 · Revance Therapeutics, Inc. · Filed Mar 16, 2018
Insider Transaction Report
Form 4
Browne L Daniel
DirectorCEO and President
Transactions
- Sale
Common Stock
2018-03-16$31.43/sh−5,452$171,348→ 141,875 total - Exercise/Conversion
Common Stock
2018-03-16$2.55/sh+20,000$51,000→ 147,327 total - Exercise/Conversion
Common Stock
2018-03-16+20,000→ 0 totalExercise: $2.55Exp: 2018-04-29→ Common Stock (20,000 underlying) - Sale
Common Stock
2018-03-15$32.80/sh−1,000$32,800→ 130,208 total - Tax Payment
Common Stock
2018-03-15$31.65/sh−2,881$91,184→ 127,327 total
Holdings
- 409(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
- [F2]Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2016 Restricted Stock Award ("RSA") for 25,000 shares. The RSA vests in three equal annual installments from March 15, 2016, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- [F3]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.975. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.
- [F5]The Option is fully vested as of April 28, 2012.